Head-to-head evidence
Fluticasone propionate/salmeterol (Advair HFA) vs salbutamol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00158834 · Phase 3 · completed
The study randomized 200 children and used double blinding with an active fluticasone comparator. Its primary endpoint was the clinical measure of asthma symptom-free days, but no results are posted, so whether that endpoint was met cannot be determined.
salbutamol
Developed by GlaxoSmithKline
NCT03528577 · Phase 3 · completed
The study randomized 128 participants in a quadruple-blind, four-period crossover design with active and placebo comparators. However, its primary endpoint was a pharmacodynamic surrogate rather than a hard clinical outcome. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: June 2027 · NCT06473779 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · salbutamol's landscape